If ASCO was defined by the exciting abundance of new options, ESMO brought the oncology community face to face with the friction of real-world delivery.
The scientific momentum was undeniable. From the practice-changing DeLLphi-305 data to the groundbreaking outcomes with ris–rez in osteosarcoma, the presidential sessions delivered the impact we’ve come to expect. Yet, running parallel to these high-profile clinical triumphs was a sobering counternarrative delivered by discussants and community oncology leaders: as therapy constructs become more biologically sophisticated, the gap between clean trial protocols and everyday clinical practice is widening.
Our three key takeaways from ESMO center around this narrative and what that means for biopharma, from communicating the clinical relevance of emerging data to anticipating the evidence and support needed for real-world use.
RAS inhibitors shift from unprecedented to crowded
You’d be forgiven for struggling to keep pace with progress in the next-generation RAS inhibitor space between ASCO and ESMO. Since the unveiling of the unprecedented data from RASolute 302 in pancreatic cancer, the conversation has rapidly shifted from “does the drug work?” to “how are we going to manage and sequence all these different agents in the clinic?”.
The fact that HCPs are asking these questions now signals that they are already thinking beyond efficacy to the realities of treatment selection, sequencing, and day-to-day management. Sponsors will need to anticipate these decisions while their clinical data are still maturing.
What will it take to succeed?
Differentiating meaningfully in this landscape will require an integrated approach: addressing critical evidence gaps, translating emerging data into a clear and credible scientific narrative, supporting clinical understanding, and anticipating patient and access barriers. The strongest strategies will connect these elements to strengthen, not complicate, the decisions stakeholders need to make.
The real-world representation gap is growing
It’s not news to anyone that the patients treated in registrational oncology trials often look fundamentally different from those managed in everyday practice, or that it was a substantial focus of discussion in the data presented at ESMO, even during the presidential sessions.
Elderly and frail patients, often with multiple comorbidities, make up a large proportion of patients being treated across many cancers in real-world practice, yet remain underrepresented in clinical trials. Consequently, clinicians frequently inherit therapies without practical guidance on how the benefits, tolerability, and treatment burden of a therapy translates to patients with frailty or multiple comorbidities. This uncertainty can complicate decision making in patient selection, dose modification, and treatment continuation – decisions that may ultimately limit the effectiveness of the treatment.
What will it take to succeed?
Although representativeness of trial populations is a broader issue that will take years to solve, sponsors can act now to address some of the consequences. By gathering input directly from clinicians, patients, and caregivers, they can identify where treatment decision-making needs better support and prioritize pragmatic, representative real-world evidence. Connecting that evidence with patient perspectives and practical education and scientific communication can help clinicians make informed treatment and management decisions for patients who differ from those enrolled in trials.
Implementation remains a barrier to innovation in capacity-constrained health systems
In the auditoria, critical appraisals of multiple clinical readouts, from radioligand therapies and personalized neoantigen vaccines to solid-tumor cell therapies, all centered strongly on practical viability. For personalized vaccines, this also brings longstanding questions about individualized manufacturing and scalability back into focus.
Novel solid-tumor cell therapies, such as TCR-T and CAR-macrophages, are showing promising early data but face biological barriers, such as tumor antigen heterogeneity and cell durability, alongside the same practical delivery challenges that face cell therapies in hematologic oncology. Years of experience in hematology with cytokine release syndrome, outpatient delivery, and manufacturing timelines can inform successful clinical implementation in solid tumors while recognizing that each modality brings distinct requirements.
Radioligand therapies bring a different but related set of delivery requirements, reinforcing the need for coordination between referring clinicians and specialist treatment teams, alongside appropriate infrastructure and radiation safety expertise.
What will it take to succeed?
Sponsors must build an understanding of potential delivery barriers alongside clinical development, drawing on lessons from established therapies and expertise specific to each modality. These insights should inform stage-appropriate planning for cross-specialty care pathways, treatment center requirements, and support for patients and referring clinicians. Health economics and outcomes research (HEOR) has a critical role in assessing resource requirements and developing the value case as evidence matures, informing future reimbursement and access decisions. The sponsors who best adapt these lessons and drive collaboration between cross-specialty stakeholders will be better positioned to support adoption of, and access to, their therapies in practice.
Driving confident decisions with OPEN Health
The scientific strides unveiled at ESMO are underpinned by a fundamental reality: demonstrating robust clinical efficacy in a trial is only the first step toward transforming patient care. Clinical differentiation matters, but the true measure of success in an oncology therapy lies in whether healthcare systems, multidisciplinary teams, and community clinicians are equipped to deliver it and whether patients have the support to understand their options and navigate care.
At OPEN Health, we bring together Medical Affairs & Communications and Evidence & Access, including HEOR and real-world evidence, and Patient Engagement to help biopharma clients navigate these challenges. From communicating the clinical relevance and limitations of early data to informing treatment delivery and payer value assessments as evidence matures, we bring together scientific evidence and insights from clinicians, patients, and other healthcare stakeholders. This helps clients make confident decisions throughout development and into clinical practice.